EGFR and neoplasm: And different from lapatinib, pyrotinib can irreversibly and simultaneously inhibit HER1, HER2, and HER4, thereby blocking RAS/RAF/MEK/MAPK and PI3K/AKT signaling pathways and inhibiting the proliferation of tumor cells (114, 115).